Avanza Fonder AB Makes New $4.96 Million Investment in Cencora, Inc. (NYSE:COR)

Avanza Fonder AB purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 22,076 shares of the company's stock, valued at approximately $4,960,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Everpar Advisors LLC acquired a new position in shares of Cencora during the fourth quarter worth approximately $229,000. Occidental Asset Management LLC raised its position in shares of Cencora by 7.9% during the fourth quarter. Occidental Asset Management LLC now owns 17,473 shares of the company's stock worth $3,926,000 after purchasing an additional 1,280 shares during the period. Eagle Rock Investment Company LLC raised its position in shares of Cencora by 2.8% during the fourth quarter. Eagle Rock Investment Company LLC now owns 39,040 shares of the company's stock worth $8,772,000 after purchasing an additional 1,048 shares during the period. Fermata Advisors LLC acquired a new position in shares of Cencora during the fourth quarter worth approximately $315,000. Finally, Ritholtz Wealth Management raised its position in shares of Cencora by 6.4% during the fourth quarter. Ritholtz Wealth Management now owns 11,233 shares of the company's stock worth $2,524,000 after purchasing an additional 673 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the transaction, the chairman now owns 306,752 shares in the company, valued at approximately $74,283,064.32. This represents a 6.55 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares of the company's stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 94,696 shares of company stock worth $22,862,734 in the last quarter. 15.80% of the stock is currently owned by company insiders.

Cencora Stock Performance

NYSE:COR traded up $1.22 during trading on Friday, reaching $242.11. The company's stock had a trading volume of 1,492,998 shares, compared to its average volume of 993,012. The firm has a market cap of $46.80 billion, a price-to-earnings ratio of 32.24, a price-to-earnings-growth ratio of 1.48 and a beta of 0.49. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm has a 50 day moving average of $237.52 and a 200-day moving average of $233.85. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $253.27.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date was Friday, November 15th. This is an increase from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio is 29.29%.

Wall Street Analyst Weigh In

COR has been the topic of a number of research reports. Wells Fargo & Company lowered their target price on Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a research report on Friday, December 13th. Robert W. Baird increased their price target on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Leerink Partners lowered their price target on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research report on Monday, October 7th. Finally, UBS Group increased their price target on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $275.60.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.